Skip to content

Study · Randomized controlled trial · 2006

17 results

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.

Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, Maloney J, Benedetto J, Zhu W, Hohneker J

International journal of obesity (2005)1 Feb 2006Cited by 74 (Europe PMC)

PMID16158082 (opens in a new tab)PMCIDPMC1540404 (opens in a new tab)DOI10.1038/sj.ijo.0803074 (opens in a new tab)PepBankPUB-16158082
Source linkPubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese adults with insulin hypersecretion, glucose AUC changes were 39-40 mg/dl h higher with octreotide than placebo.

    In plain wordsIn obese adults with insulin hypersecretion, glucose exposure increased more with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    IncreaseGlucose AUC change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Difference in mean change of blood glucose AUC(0-180 min) vs placebo, OGTT
    39 to 40 mg/dl h
    octreotide LAR vs placebo

    Source sentences

    Summary
    Mean changes of blood glucose AUC(0-180 min) during an oral glucose tolerance test in patients taking octreotide LAR were 39-40 mg/dl h higher than those on placebo.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults, 7-21% on octreotide versus 11% on placebo lost at least 5% body weight; the difference was not significant.

    In plain wordsIn obese adults, substantial weight-loss rates did not differ significantly between octreotide and placebo.

    Peptide
    Octreotide
    Outcome
    No significant changeAt least five percent weight-loss responders
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Patients with >=5% weight loss from baseline
    7 to 21%
    octreotide LAR groups
    Patients with >=5% weight loss from baseline
    11%
    placebo group

    Source sentences

    Summary
    A total of 7-21% of the patients taking octreotide LAR reached a 5% or greater decrease in body weight from Baseline, compared to 11% for the placebo group. This was not statistically significant.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese adults with insulin hypersecretion, the mean difference from placebo in percent weight change was -1.98% with octreotide 40 mg.

    In plain wordsIn obese adults with insulin hypersecretion, weight change was numerically lower with octreotide 40 mg than placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePercent weight change at 40 mg versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 mg · 6 monthsAs given in this study (human).

    Measurements

    Mean difference from placebo in percent weight change
    −1.98%
    octreotide LAR 40 mg, 6 months

    Source sentences

    Summary
    After 6 months of treatment, patients receiving 40 or 60 mg of octreotide LAR experienced statistically significant weight loss compared to baseline, with mean differences from placebo in percent weight change of -1.98 and -1.87%, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with insulin hypersecretion, the mean difference from placebo in percent weight change was -1.87% with octreotide 60 mg.

    In plain wordsIn obese adults with insulin hypersecretion, weight change was numerically lower with octreotide 60 mg than placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePercent weight change at 60 mg versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    60 mg · 6 monthsAs given in this study (human).

    Measurements

    Mean difference from placebo in percent weight change
    −1.87%
    octreotide LAR 60 mg, 6 months

    Source sentences

    Summary
    After 6 months of treatment, patients receiving 40 or 60 mg of octreotide LAR experienced statistically significant weight loss compared to baseline, with mean differences from placebo in percent weight change of -1.98 and -1.87%, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  5. 05HumanNon-randomized trialEfficacy outcome

    In obese adults with insulin hypersecretion, octreotide 40 mg significantly reduced weight from baseline after 6 months.

    In plain wordsIn obese adults with insulin hypersecretion, octreotide 40 mg reduced weight from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseWeight change at 40 mg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 mg · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After 6 months of treatment, patients receiving 40 or 60 mg of octreotide LAR experienced statistically significant weight loss compared to baseline, with mean differences from placebo in percent weight change of -1.98 and -1.87%, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  6. 06HumanNon-randomized trialEfficacy outcome

    In obese adults with insulin hypersecretion, octreotide 60 mg significantly reduced weight from baseline after 6 months.

    In plain wordsIn obese adults with insulin hypersecretion, octreotide 60 mg reduced weight from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseWeight change at 60 mg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    60 mg · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After 6 months of treatment, patients receiving 40 or 60 mg of octreotide LAR experienced statistically significant weight loss compared to baseline, with mean differences from placebo in percent weight change of -1.98 and -1.87%, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  7. 07HumanNon-randomized trialEfficacy outcome

    In obese adults with insulin hypersecretion, octreotide 40 mg reduced BMI by 0.73 kg/m2 from baseline.

    In plain wordsIn obese adults with insulin hypersecretion, octreotide 40 mg reduced BMI from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseBMI change at 40 mg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 mg · 6 monthsAs given in this study (human).

    Measurements

    Mean BMI change from baseline
    −0.73 kg/m2
    octreotide LAR 40 mg

    Source sentences

    Summary
    This finding was accompanied by statistically significant mean decreases in BMI compared to baseline, that is, a mean decrease of 0.73 and 0.79 kg/m2 for the 40 and 60 mg treatment arms, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  8. 08HumanNon-randomized trialEfficacy outcome

    In obese adults with insulin hypersecretion, octreotide 60 mg reduced BMI by 0.79 kg/m2 from baseline.

    In plain wordsIn obese adults with insulin hypersecretion, octreotide 60 mg reduced BMI from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseBMI change at 60 mg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    60 mg · 6 monthsAs given in this study (human).

    Measurements

    Mean BMI change from baseline
    −0.79 kg/m2
    octreotide LAR 60 mg

    Source sentences

    Summary
    This finding was accompanied by statistically significant mean decreases in BMI compared to baseline, that is, a mean decrease of 0.73 and 0.79 kg/m2 for the 40 and 60 mg treatment arms, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  9. 09HumanNon-randomized trialEfficacy outcome

    In obese adults with insulin hypersecretion, weight loss progressed during 6 months of higher-dose octreotide treatment.

    In plain wordsIn obese adults with insulin hypersecretion, weight loss progressed during higher-dose octreotide treatment.

    Peptide
    Octreotide
    Outcome
    DecreaseWeight-loss progression
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 or 60 mg · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The observed weight loss was progressive during the 6-month treatment in the two higher dose groups.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  10. 10HumanNon-randomized trialEfficacy outcome

    In obese adults with insulin hypersecretion, 40 mg was the lowest octreotide dose with significant weight loss after 6 months.

    In plain wordsIn obese adults with insulin hypersecretion, 40 mg was the lowest octreotide dose with significant weight loss.

    Peptide
    Octreotide
    Outcome
    Not applicableLowest dose with significant weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 mg · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The lowest dose to reach statistical significance in weight loss after 6 months' treatment was 40 mg.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  11. 11HumanNon-randomized trialEfficacy outcome

    In obese adults receiving octreotide, quality of life, body fat, leptin, depression scores and macronutrient intake showed no significant changes.

    In plain wordsIn obese adults receiving octreotide, the listed quality-of-life, body-composition, hormone, mood and dietary measures did not change significantly.

    Peptide
    Octreotide
    Outcome
    No significant changeQuality of life, body fat, leptin, depression and macronutrient intake
    Study

    n: not reported in source

    Outcome group
    Other Outcomes · Whole body
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant changes in QoL scores, body fat, leptin concentration, Beck Depression Inventory, or macronutrient intake.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  12. 12HumanNon-randomized trialSafety outcome

    In obese adults receiving octreotide, diarrhea was among the most common adverse events.

    In plain wordsIn obese adults receiving octreotide, diarrhea was a common adverse event.

    Peptide
    Octreotide
    Outcome
    Not applicableDiarrhea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  13. 13HumanNon-randomized trialSafety outcome

    In obese adults receiving octreotide, headache was among the most common adverse events.

    In plain wordsIn obese adults receiving octreotide, headache was a common adverse event.

    Peptide
    Octreotide
    Outcome
    Not applicableHeadache
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  14. 14HumanNon-randomized trialSafety outcome

    In obese adults receiving octreotide, cholelithiasis was among the most common adverse events.

    In plain wordsIn obese adults receiving octreotide, gallstones were a common adverse event.

    Peptide
    Octreotide
    Outcome
    Not applicableCholelithiasis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  15. 15HumanNon-randomized trialSafety outcome

    In obese adults receiving octreotide, nausea was among the most common adverse events.

    In plain wordsIn obese adults receiving octreotide, nausea was a common adverse event.

    Peptide
    Octreotide
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  16. 16HumanNon-randomized trialSafety outcome

    In obese adults receiving octreotide, abdominal pain was among the most common adverse events.

    In plain wordsIn obese adults receiving octreotide, abdominal pain was a common adverse event.

    Peptide
    Octreotide
    Outcome
    Not applicableAbdominal pain
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.
  17. 17HumanObservational studyEfficacy outcome

    In Caucasian obese adults with above-median insulin secretion, higher-dose octreotide was associated with 3.5-3.8% weight loss at month 6.

    In plain wordsIn Caucasian obese adults with high insulin secretion, higher-dose octreotide was linked to weight loss.

    Peptide
    Octreotide
    Outcome
    DecreaseWeight loss in high-insulin Caucasian subgroup
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 or 60 mg · 6 monthsAs given in this study (human).

    Measurements

    Weight loss at month 6
    3.5 to 3.8%
    post hoc subgroup: Caucasian patients with CIR(gp) >= 1.43, 40 or 60 mg groups

    Source sentences

    Summary
    Post hoc analysis revealed a 3.5-3.8% weight loss at month 6 in the two higher dose groups among Caucasian patients having insulin secretion greater than the median of the cohort, defined as CIR(gp) (corrected insulin response at the glucose peak) > or = 1.43.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
    Summary · context
    A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30-65 kg/m2) and evidence of insulin hypersecretion were enrolled.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.